Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’s China Sales Grow 25 Percent

This article was originally published in PharmAsia News

Executive Summary

Novartis's China sales grew by 24.8 percent to reach 2.58 billion yuan ($362.7 million) in 2007; in particular, its animal health business jumped 50.9 percent. Beijing Novartis enjoyed sales of 2 billion yuan ($281 million), a rise of 27 percent. Six of Novartis's drug brands garnered over 100 million yuan ($14 million) each: anti-hypertensive medicine Diovan ranked number one in market share while sales of another anti-hypertensive Lotensin crossed 400 million yuan ($56.2 million). The company's vaccines introduced into China in mid-2006 reaped more than 50 million yuan ($7 million) in 2007. Novartis forecasts a growth of more than 20 percent for China in 2008. Its new R&D park in Shanghai is about to begin construction while its Suzhou plant will soon go into production. (Click here for more - Chinese Language)

You may also be interested in...



Ahead Of Ryoncil’s Advisory Committee, Citizen Petition Opposes Approval For Pediatric GVHD

Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.

Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.

Like Consumer Health Ad Claims About COVID-19, Customer Testimonials Are False And Misleading

Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading. 

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel